Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use

Abstract

Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health problem. The prevalence of AD is growing dramatically, especially in low-and middle-income countries, and will reach 131.5 million cases worldwide by 2050. Therefore, developing a disease-modifying therapy capable of delaying or even preventing the onset and progression of AD has become a world priority, and is an unmet need. The pathogenesis of AD, considered as the result of an imbalance between resilience and risk factors, begins many years before the typical clinical picture develops and involves multiple pathophysiological mechanisms. Since the pathophysiology of AD is multifactorial, it is not surprising that all attempts done to modify the disease course with drugs directed towards a single therapeutic target have been unsuccessful. Thus, combined modality therapy, using multiple drugs with a single mechanism of action or multi-target drugs, appears as the most promising strategy for both effective AD therapy and prevention. Cerebrolysin, acting as a multitarget peptidergic drug with a neurotrophic mode of action, exerts long-lasting therapeutic effects on AD that could reflect its potential utility for disease modification. Clinical trials demonstrated that Cerebrolysin is safe and efficacious in the treatment of AD, and may enhance and prolong the efficacy of cholinergic drugs, particularly in moderate to advanced AD patients. In this review, we summarize advances of therapeutic relevance in the pathogenesis and the biomarkers of

Ellagic Acid Modulates the Amyloid Precursor Protein Gene via Superoxide Dismutase Regulation in the Entorhinal Cortex in an Experimental Alzheimer’s Model

“…Furthermore, ROS can trigger a lack of oxygen in the nervous tissue and Aβ toxicity, leading to neurodegeneration [ 58 ]. It has been reported that the amount and distribution of NFTs is directly related to the severity and duration of dementia [ 59 ].…”

Role of Cerebrolysin® in Rehabilitation in Ischemic Stroke: A Case Report

“…The clinical research on Cerebrolysin ® in the late subacute to chronic phases is still ongoing, with only 1 published retrospective study on the reduction of spasticity, and 1 in patients with minimally conscious state after stroke [ 16 , 17 ]. Additionally, sufficient safety data in several neurological conditions, such as subarachnoid hemorrhage, traumatic brain injury, and mild cognitive impairment and dementia, have been published [ 18 – 20 ].…”

Asparagopsis Genus: What We Really Know About Its Biological Activities and Chemical Composition

“…Acetylcholinesterase inhibition is the basis of most approved therapies for Alzheimer’s disease [ 137 ], which is the most prevalent neurocognitive disorder in the world and is estimated to be responsible for about two thirds of the dementia cases worldwide [ 138 ]. Since current therapeutics have limited potential and serious side effects, researchers have been looking for new therapeutic agents in the natural world, including marine algae.…”